Alerta

ALK POLYPEPTIDES AND METHODS OF USE THEREOF

Resumen de: US2025325644A1

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF

Resumen de: US2025326856A1

Novel chimeric and/or humanized forms of the anti-CD45 BC8 antibody are described. The disclosed chimeric or humanized antibodies can be used as research, diagnostic, or therapeutic tools against CD45-related disorders, such as hematologic malignancies including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), other myeloid and lymphoid disorders, other cancers, as well as non-malignant disorders, such as autoimmune disorders, infections, inherited blood disorders, and metabolic disorders.

HETERO (AROMATIC) RING-SUBSTITUTED CYCLIC DIAMINE COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING AND/OR PREVENTING TUMORS

Resumen de: WO2025218293A1

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and/or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

REAGENTS AND METHODS FOR DETECTING OR MODULATING CBL AND/OR CBL-B IN PATIENTS

Resumen de: WO2025217743A1

Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. The diagnosis of SLE is challenging because signs and symptoms vary considerably from person to person, may change over time, and may overlap with those of many other disorders. There is thus a need for better tools and assays for the diagnosis and assessment of SLE. The present application discloses novel methods for the diagnosis and follow-up of SLE based on the detection of the levels of Casitas B-lineage lymphoma (CBL) and/or CBL-B in T lymphocytes from a subject, as well as novel methods for treating a subject suffering from SLE or preventing the development of SLE in an at-risk subject through the administration of an agent that increases the expression or activity of CBL and/or CBL-B in T lymphocytes from the subject, and/or the depletion of ICOS+ T cells.

ANTI-CLL1 SINGLE-DOMAIN ANTIBODY AND USE THEREOF

Resumen de: EP4635981A1

The present invention relates to an anti-CLL1 single-domain antibody and use thereof, specifically, to a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity and can specifically target CLL1-positive cells, and can be applied to the detection of CLL1 expression in bone marrow cells of acute myeloid leukemia (AML) patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating CLL1 target-related diseases (such as acute myeloid leukemia, myelodysplastic syndromes, or chronic myeloid leukemia), and can also be used in the preparation of CLL1-targeting chimeric antigen receptor (CAR) cells or diagnostic kits for CLL1 protein detection and the like. The single-domain antibody drug has a stable structure, small molecular size, ease of recombinant expression, and low production cost. It can be used alone or employed as a drug delivery system to carry related drugs, which has broad prospects and important significance in the fields of pharmaceutical application, clinical diagnosis, and related fields.

METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Resumen de: ZA202000070B

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).

SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

Resumen de: US2025320229A1

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

Resumen de: US2025320225A1

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.

RECOMBINANT RECEPTORS BINDING B CELL ACTIVATION FACTOR RECEPTOR AND USES THEREOF

Resumen de: US2025319130A1

Recombinant receptors with a binding domain that binds B cell activation factor receptor (BAFF-R) are disclosed. Recombinant receptors include chimeric antigen receptors (CAR) having an anti-BAFF-R binding domain, a transmembrane domain, a CD3ζ/4-1BB intracellular signaling domain, and a spacer. Methods and systems to treat BAFF-R-expressing cancers, such as mantle cell lymphoma (MCL), multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL), are also provided. The recombinant receptors disclosed herein can bind and elicit cytotoxic effects even in low antigen density conditions.

USE OF ANTI-HA-1 AND ANTI-HA-2 BINDING PROTEINS FOR TREATMENT OF AML, ALL, AND MDS

Resumen de: WO2025217035A2

The present disclosure encompasses, among other things, methods and compositions for use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT. The present disclosure relates, at least in part, to T cells engineered to express particular T Cell Receptors (TCRs) and their use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT,

BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF FOR TARGETED DELIVERY

Resumen de: US2025319036A1

Described herein, in some aspects, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasizes to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

COMBINATION TREATMENT OF GLOFITAMAB AND CHEMOTHERAPY

Resumen de: WO2025215124A2

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES

Resumen de: US2025320298A1

The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

METHOD FOR EXAMINING DISEASE PROGRESSION OF ENZOOTIC BOVINE LEUKOSIS, PRIMER, CFDNA QUANTITATION KIT, AND KIT FOR EXAMINING DISEASE PROGRESSION OF ENZOOTIC BOVINE LEUKOSIS

Resumen de: WO2025216320A1

Provided is a method for examining disease progression of enzootic bovine leukosis, the method comprising a step (A) for quantifying cell-free DNA derived from proviral DNA of bovine leukemia virus, in a sample containing cell-free DNA of an animal of interest.

METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS

Nº publicación: US2025319111A1 16/10/2025

Solicitante:

SOBI INC [US]
OHIO STATE INNOVATION FOUND [US]
Sobi, Inc,
Ohio State Innovation Foundation

Resumen de: US2025319111A1

Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided.